Pfizer begins first human tests of potential arthritis and lupus drug
NCT ID NCT07235163
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new drug called PF-08065010 in 100 healthy adults aged 18 to 65. The goal is to check its safety and how the body processes it, as a first step toward possibly treating rheumatoid arthritis and lupus. Participants receive either the drug or a placebo as a shot or IV, with frequent monitoring over several months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- PF-08065010
- What this could lead to
- If successful, this could pave the way for a new treatment option for rheumatoid arthritis and lupus.
- What could go wrong
- This is an early Phase 1 safety study in healthy people, not patients. The drug may not work or could have side effects in later trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test